Current Evidence on Thyroid Lobectomy for Medullary Thyroid Cancer

Summary

Lobectomy may be considered in select patients with sporadic medullary thyroid cancer (MTC), though total thyroidectomy with central neck dissection remains the standard of care. The evidence base is evolving, with growing data supporting comparable oncologic outcomes for carefully selected patients.

Guideline Recommendations

The NCCN Thyroid Carcinoma Guidelines (v2.2026) recommend total thyroidectomy with central neck dissection (level VI) as the standard primary treatment for MTC. However, the guidelines now explicitly state that “lobectomy can be considered in select cases without RET pathogenic variant if no concerns for contralateral nodules.” This represents a notable shift toward acknowledging lobectomy as an option.

For MTC diagnosed after initial thyroid surgery (e.g., lobectomy), the NCCN notes that completion thyroidectomy may not be necessary unless there is a positive germline RET pathogenic variant or radiographic evidence of disease (biopsy-proven residual neck disease).

The ATA Guidelines similarly state that completion thyroidectomy following hemithyroidectomy is not indicated unless the patient has a RET germline mutation, significant postoperative calcitonin elevation, or imaging showing residual MTC. In a prospective study of 15 patients with sporadic MTC treated by hemithyroidectomy, 80% achieved biochemical cure.

Hereditary MTC (MEN2A/MEN2B) remains a strict indication for total thyroidectomy, as the likelihood of bilateral disease approaches 100%.

Key Evidence Supporting Lobectomy in Sporadic MTC

A 2026 systematic review and meta-analysis in JAMA Otolaryngology (9 studies, 1,371 patients) found that lobectomy was associated with comparable oncologic outcomes to total thyroidectomy in selected patients with sporadic MTC:

– Mortality: No difference at 5 years (RR 0.30; 95% CI 0.07–1.35) or beyond (RR 1.00; 95% CI 0.40–2.47)

– Overall survival at 5 years: Similar (RR 1.02; 95% CI 0.94–1.11)

– Biochemical cure: No difference at 5 or beyond 5 years

– Structural recurrence at 5 years: No difference (OR 0.45; 95% CI 0.14–1.49), though total thyroidectomy was associated with lower recurrence beyond 5 years (OR 7.26; 95% CI 1.07–49.21) — a finding with very wide confidence intervals

– Postoperative complications: More common with total thyroidectomy

Multiple SEER-based analyses corroborate these findings:

– A propensity-matched study (122 pairs, median follow-up 99 months) showed no significant difference in 10-year overall survival (85.2% vs. 83.1%) or disease-specific survival between total thyroidectomy and lobectomy for localized MTC.

– Another SEER analysis of T1N0/1M0 MTC (398 patients, median follow-up 8.75 years) found no survival difference between approaches (cancer-specific mortality HR 0.44, p = 0.23).

– A 2025 SEER analysis with Chinese cohort validation confirmed no survival difference and demonstrated significantly more adverse events with total thyroidectomy, including transient hypocalcemia (p < 0.001) and vocal cord paralysis (p < 0.025).

Occult Contralateral Disease

A key concern with lobectomy is missing contralateral foci. A multi-institutional JAMA Otolaryngology study found that the prevalence of sonographically occult contralateral disease in sporadic MTC was only 5.0%, with a 95.7% reduction in odds compared to germline disease (adjusted OR 0.034). Among patients who underwent lobectomy alone, 41.7% achieved undetectable calcitonin levels. A 2026 European study found zero cases of occult contralateral disease in 48 patients with sporadic MTC when high-quality preoperative ultrasound was available.

Patient Selection Criteria for Lobectomy

Based on the available evidence, lobectomy with ipsilateral central neck dissection may be appropriate when all of the following are met:

– Sporadic disease (no germline RET pathogenic variant)

– Unifocal tumor confined to one lobe with no contralateral nodules on ultrasound

– Clinically node-negative (cN0) with preoperative calcitonin ≤250 pg/mL

– No extrathyroidal extension

– Tumor size <2 cm (most studied population)

– Absence of desmoplastic stroma reaction on intraoperative frozen section (if available)

—Important Caveats

Important Caveats

All existing data are retrospective, with inherent selection bias — patients who underwent lobectomy likely had lower-risk disease. The meta-analysis signal of potentially higher structural recurrence beyond 5 years with lobectomy warrants attention, though confidence intervals were very wide. Calcitonin surveillance is more complex after lobectomy, as residual normal C cells may produce low-level calcitonin, complicating interpretation. Prospective randomized trials are needed to definitively establish the safety of lobectomy in this setting.

Key References

– Lincango EP et al. Total Thyroidectomy vs Lobectomy for Sporadic Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2026.

– Mao YV et al. Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci. JAMA Otolaryngol Head Neck Surg. 2024.

– Wells SA et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 2015.

– Liang W et al. Total Thyroidectomy vs Thyroid Lobectomy for Localized Medullary Thyroid Cancer in Adults: A Propensity-Matched Survival Analysis. Surgery. 2022.

– Yang J et al. Comparison of Lobectomy vs Total Thyroidectomy for Medullary Thyroid Carcinoma: A SEER Analysis With Chinese Cohort Validation. Oncologist. 2025.

– Spörlein A et al. Is Hemithyroidectomy Enough? Low Risk of Occult Contralateral Disease in Sporadic Medullary Thyroid Cancer. Eur Arch Otorhinolaryngol. 2026.

– Park H et al. Preoperative Identification of Low-Risk Medullary Thyroid Carcinoma: Potential Application to Reduce Total Thyroidectomy. Sci Rep. 2023.

– NCCN Thyroid Carcinoma Guidelines, v2.2026.